A third dose of Novavax vaccine, NVX-CoV2373 is recommended for immunocompromised persons by the World Health Organization (WHO).

SAGE, the WHO's Strategic Advisory Group of Experts on Immunization recommended the third dose of vaccine. The recommendation was issued alongwith a series of others, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those living with HIV.

The vaccine could be used in pregnant women if the benefits of vaccination outweigh the potential risks, the independent experts said after reviewing Novavax data.

Novavax vaccine was listed for emergency use by the WHO on Friday. The vaccine is produced by the Serum Institute of India, the world's biggest vaccine maker. The vaccine makes way for its use in low and middle income countries where the inoculation rates are much slower than in Europe.

Novavax said on Monday that further to WHO's emergency use listing for the company's version of the vaccine, it will distribute the vaccine in Europe and other markets.

The company also said that administering of the first booster doses of NVX-CoV2373 has begun in a late stage trial.